FBRX Overview

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.

Wall Street analysts forecast FBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for FBRX is65.00 USD with a low forecast of 65.00 USD and a high forecast of 65.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Forte Biosciences Inc revenue for the last quarter amounts to -24.57M USD, increased 234.25

Forte Biosciences Inc. EPS for the last quarter amounts to -16466000.00 USD, increased 64.00

Forte Biosciences Inc (FBRX) has 19 emplpoyees as of April 20 2026.

Today FBRX has the market capitalization of 664.68M USD.